Caina Technology Co., Ltd. Class A

Caina Technology Co., Ltd. Class A

SSZSE:301122
45.30
CNY
-1.11
(-2.39%)
0.09EPS
597.90P/E
8.15BMarket Cap
Apr 13Next Earn
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.19
1.83
2.24
5.81
4.81
5.06
3.35
3.14
3.17
4.54
Basic EPS, GAAP
0.16
0.26
0.4
1.58
1.42
1.76
0.92
0.43
0.05
0.11
Free Cash Flow per Basic Share
-0.43
0.02
0.11
1.13
0.68
-0.28
-0.91
0.03
-0.66
- -
Dividend per Share
0.04
0.06
0.07
0.27
- -
0.36
0.35
0.4
0.27
0.06
Book Value per Share
1.16
1.43
2.11
4.14
5.56
14.2
14.78
14.81
15.04
15.52
Tangible Book Value per Share
0.89
1.16
1.5
3.6
5.09
13.86
14.43
14.39
14.63
14.75
Basic Weighted Avg Shares
78
78
81
87
92
92
122
123
112
121
Sales/Revenue/Turnover
93
143
181
505
442
465
410
388
357
551
Operating Margin (%)
12.23
18.86
24.95
35.15
34.09
29.3
25.58
18.68
0.9
4.08
Depreciation Expense
9
11
13
16
21
28
32
40
55
- -
Net Income, GAAP
13
20
32
137
131
162
113
53
6
14
Effective Tax Rate (%)
0.74
5.74
20.4
15.65
13.88
11.82
13.55
8.58
- -
- -
Profit Margin (%)
13.53
14.3
17.83
27.13
29.56
34.77
27.42
13.69
1.58
2.46
Working Capital
-6
-26
-11
142
225
1,296
1,215
1,006
897
853
LT Debt
49
47
- -
- -
- -
- -
- -
32
28
24
Total Equity
91
111
174
379
510
1,736
1,807
1,814
1,844
1,914
Return on Invested Capital (%)
- -
11.72
14.18
42.94
28.83
14.06
6.31
2.89
- -
- -
Return on Capital (%)
- -
24.41
23.13
45.98
28.81
14.41
6.35
2.96
- -
- -
Return on Common Equity (%)
- -
20.31
22.71
49.56
29.38
14.41
6.35
2.94
0.31
0.73

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
138
143
143
LT Borrowings
- -
- -
- -
LT Finance Leases
27
25
24
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
122
122
122
Market Capitalization
3,521
3,595
8,150

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,069
1,134
1,153
Cash, Cash Equivalents & STI
780
761
741
Accounts Receivable, Net
80
90
101
Inventories
130
152
171
Total Current Liabilities
325
296
300
Payables & Accruals
- -
- -
- -
ST Debt
138
143
143
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
56.19%
1.63%
Free Cash Flow
- -
-422.37%
-2,158.49%
Net Income, GAAP
- -
-30.69%
-89.41%
Sales/Revenue/Turnover
- -
-6.51%
-8.04%
Total Cash Common Dividend
- -
2,452.77%
-37.5%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
111
84
98
96
388
2025
73
86
- -
111
357
2026
141
131
168
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.2
0.07
0.2
-0.04
0.43
2025
0.06
0.01
- -
-0.02
0.05
2026
0.11
-0.03
0.05
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.4
2025
- -
- -
- -
- -
0.27
2026
0.01
0.05
0.01
- -
- -

Company Description

CEO
Jun Lu
Full Time Employees
1,057
Sector
Health technology
Industry
Medical specialties
Address
No. 23, Huaxi Road Jiangyin JS China 214421
IPO Date
Jan 26, 2022
Website
caina.ltd
Business
Caina Technology Co., Ltd. (301122.SZ) manufactures and sells disposable syringes, needles and related medical consumables principally for human healthcare, veterinary and laboratory applications. The company produces disposable sterile safe self-destructing syringes; disposable insulin syringes; disposable sterile insulin pen needles; disposable sterile blood collection needles; nutritional interface syringes; safety needles; copper-seat needles; aluminum-plastic injection needles; sheathed syringes; continuous syringes; reusable syringes; petri dishes; bacterial filter boxes; polypropylene hub disposable needles; hypodermic reusable needles; detectable needles; TPX syringes; and plastic injectors, among other sterile medical devices. Founded in 2004 and headquartered in Jiangyin, China, Caina Technology operates three primary business segments spanning medical equipment, animal equipment and laboratory consumables, with products supplied domestically and internationally through OEM and ODM services leveraging advanced intelligent manufacturing facilities including automated clean rooms and sterilization lines. In recent developments, the company listed on the Shenzhen Stock Exchange in January 2022 and continues to invest in R&D through centers such as the Jiangyin Safe Self-Destructing Syringe Engineering Technology Research Center and Wuxi Veterinary Piercing Device Engineering Technology Research Center, though it reports declining revenues and net profits including a 15.86% revenue drop to 246 million yuan and 85.64% net profit decline in the first three quarters of 2025.